Related Experiment Videos
Dalbavancin (Biosearch Italia/Versicor).
Matthias Steiert1, Franz-Josef Schmitz
1Institute for Medical Microbiology Virology, Universitätsklinikum Düsseldorf, Germany.
Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
Summary
Dalbavancin, a novel glycopeptide antibiotic, is in phase II trials for Gram-positive infections. This semisynthetic derivative shows promise for treating skin infections and bacteremia.
Area of Science:
- Pharmacology
- Infectious Diseases
- Drug Development
Background:
- Dalbavancin is a novel semisynthetic glycopeptide derivative of A-40926.
- It is being developed for the potential treatment of Gram-positive bacterial infections.
Purpose of the Study:
- To evaluate the efficacy and safety of dalbavancin in clinical trials.
- To assess dalbavancin's potential for treating Gram-positive infections, including skin infections and bacteremia.
Main Methods:
- Dalbavancin entered phase II clinical trials in the US in May 2001.
- Phase II trials for skin infections and bacteremia were ongoing as of January 2002.
Main Results:
- Dalbavancin is a dimethylaminopropyl amide derivative of A-40926, differing from MDL-63246 in its acylamino sugar component.
- The development of MDL-63246 has been discontinued.
Conclusions:
- Dalbavancin is progressing through clinical development for Gram-positive infections.
- Regulatory filings and market launch are anticipated in the coming years, with significant sales projections.